<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2501221639
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEUROGAB 75 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PREGABALIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAMMAM PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1898]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAMMAM PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Neurogab</strong> belongs to a group of medicines used to treat epilepsy,&nbsp;neuropalhic pain and Generalized Anxiety Disorder {GAD) in&nbsp;adults.&nbsp;<br /><strong>Peripheral and central neuropathic pain:</strong> <strong>Neurogab</strong> is used to&nbsp;treat long lasting pain caused by damage to the nerves. A variety of diseases can cause peripheral neuropathic pain, such as&nbsp;diabetes or shingles. Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles. Peripheral and central neuropathic pain may also be associated with mood changes, sleep disturbance, fatigue (tiredness), and can have an impact on physical and social functioning and overall quality of life.&nbsp;</p><p><strong>Epilepsy: Neurogab</strong> is used to treat a certain form of epilepsy (partial&nbsp;seizures with or without secondary generalization) in adults. Your doctor will prescribe <strong>Neurogab</strong> for you to help treat your epilepsy when your current treatment is not controlling your condition. You should take <strong>Neurogab</strong> in addition to your current treatment. <strong>Neurogab</strong> is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.&nbsp;</p><p><strong>Generalized Anxiety Disorder: </strong>Neurogab is used to treat&nbsp;Generalized Anxiety Disorder (GAD). The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control. GAD can also cause restlessness or feeling keyed up or on edge, being easily fatigued (tired), having difficulty concentrating or mind going blank, feeling irritable, and having muscle tension or sleep disturbance. This is different to the stresses and strains of everyday life.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Neurogab&nbsp;</strong><br />If you are allergic (hypersensitive) to pregabalin or any of the other ingredients of Neurogab.&nbsp;<br /><strong>Take special care with Neurogab&nbsp;</strong><br />The safety and efficacy in children and adolescents (under 18 years of age) has not been established and therefore, pregabalin should not be used in this age group.&nbsp;</p><ul><li>Some patients taking pregabalin have reported symptoms suggesting an allergic reaction. These symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. Should you experience any of these reactions, you should contact your physician immediately.&nbsp;</li><li><strong>Neurogab</strong> has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients. Therefore, you should be careful until you are used to any effect the medicine might have.&nbsp;</li><li><strong>Neurogab</strong> may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision. Some patients with diabetes who gain weight while taking <strong>Neurogab</strong> may need an alteration in their diabetic medicines.</li><li>Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Neurogab and the severity of these effects may be increased when taken together.&nbsp;</li><li>There have been reports of heart failure in some patients when laking pregabalin; these patients were mostly elderly with cardiovascular conditions. <strong>Before taking this medicine you should tell your doctor if you have a history of heart disease. </strong></li><li>There have been reports of kidney failure in some patients when taking pregabalin. If while taking <strong>Neurogab</strong> you notice decreased urination, you should tell your doctor as stopping the medicine may improve this.&nbsp;</li><li>A small number of people being treated with anti-epileptics such as <strong>Neurogab</strong> have had thoughts of harming or killing themselves. If at any lime you have these thoughts, immediately ccntact your doctor.&nbsp;</li><li>When <strong>Neurogab</strong> is taken with other medicines that may cause constipation (such as some types of pain medicines) ii is possible that gastrointestinal problems may occur (e.g. ccnstipation, blocked or paralyzed bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem.&nbsp;</li><li>Before laking this medicine you should tell your doctor if you have a history of alccholism or drug dependence. Let your doctor know if you think you need more medicine than prescribed.&nbsp;</li><li>There have been reports of convulsions when taking pregabalin or shortly after stopping pregabalin. If you experience a convulsion, contact your doctor immediately.&nbsp;</li><li>There have been reports of reduction in brain function (encephalopathy) in some patients taking pregabalin when they have other conditions. Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease.&nbsp;</li></ul><p><strong>Taking other medicines&nbsp;</strong><br />Before taking any new medicine with <strong>Neurogab</strong> you should talk to your doctor. Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&nbsp;<br /><strong>Neurogab</strong> and certain other medicines may influence each other (interaction). When taken with certain other medicines, <strong>Neurogab</strong>&nbsp;may potentiate the side effects seen with these medicines, including&nbsp;respiratory failure and coma. The degree of dizziness, sleepiness&nbsp;and decreased concentration may be increased if <strong>Neurogab</strong> is taken&nbsp;together with medicinal products containing:</p><p>- Oxycodone (used as a pain-killer).&nbsp;</p><p>- Lorazepam (used for treating anxiety).&nbsp;<br />- Alcohol&nbsp;<br /><strong>Neurogab</strong> may be taken with oral contraceptives.&nbsp;<br /><strong>Taking Neurogab with food and drink&nbsp;<br />Neurogab</strong> capsules may be taken with or without food.&nbsp;<br />It is advised not to drink alcohol while taking Neurogab&nbsp;<br /><strong>Pregnancy and breast-feeding&nbsp;</strong><br />Ask your doctor or pharmacist for advice before taking any medicine. <strong>Neurogab</strong> should not be taken during pregnancy, unless you are told otherwise by your doctor. Effective contraception must be used by women of child-bearing potential. Contact your doctor immediately if you become pregnant, think you might be pregnant or are planning to become pregnant while taking Neurogab.&nbsp;<br />It is not recommended to breast-feed your baby while using Neurogab as it is not known if pregabalin may be found in breast milk. Ask your doctor or pharmacist for advice before taking any medicine while breast-feeding.&nbsp;<br /><strong>Driving and using machines&nbsp;<br />Neurogab</strong> may produce dizziness, sleepiness and decreased concentration. You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.</p><p><strong>Important information about some of the ingredients of Neurogab: </strong></p><p><strong>Neurogab</strong> contains lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before laking this medicinal product.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Neurogab</strong> exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are not sure. Your doctor will determine what dose is appropriate for you. <strong>Peripheral and central neuropathic pain, epilepsy or Generalized Anxiety Disorder:&nbsp;</strong><br />Take the number of capsules as instructed by your doctor.&nbsp;<br />The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.&nbsp;<br />Your doctor will tell you to take <strong>Neurogab</strong> either twice or three limes a day. For twice a day take Neurogab once in the morning and once in the evening, at about the same time each day. For three times a day take <strong>Neurogab</strong> once in the morning, once in the afternoon and once in the evening, at about the same lime each day.&nbsp;<br />If you have the impression that the effect of <strong>Neurogab</strong> is too strong or too weak, talk to your doctor or pharmacist.&nbsp;</p><p>If you are an elderly patient (over 65 years of age), you should take <strong>Neurogab</strong> normally except if you have problems with your kidneys. Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.&nbsp;<br />Swallow the capsule whole with water.&nbsp;<br />Continue taking <strong>Neurogab</strong> until your doctor tells you to stop.&nbsp;</p><p><strong>If you take more Neurogab than you should&nbsp;</strong><br />Call your doctor or go to the nearest hospital emergency unit immediately. Take your box of <strong>Neurogab</strong> capsules with you. You may feel sleepy, ccnfused, agitated or restless as a result of taking more <strong>Neurogab</strong> than you should.&nbsp;<br /><strong>If you forget to take Neurogab&nbsp;</strong><br />II is important to take your <strong>Neurogab</strong> capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten dose.&nbsp;<br /><strong>If you stop taking Neurogab&nbsp;</strong><br />Do not stop taking <strong>Neurogab</strong> unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of 1 week. If you have any further questions on the use of this product, ask your doctor or pharmacist.&nbsp;<br />After stopping long and short-term pregabalin treatment, you need to know that you may experience certain side effects. These include, trouble sleeping, headache, nausea, feeling anxious, diarrhea, flu-like symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness. It is not clear at this time whether these symptoms occur more commonly or severely if you have been taking pregabalin for a longer period of time.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Neurogab can have side effects, although not everyone gets them.&nbsp;<br /><strong>Very common side effects (&ge;1/10):</strong></p><p>Dizziness, tiredness.&nbsp;<br /><strong>Common side-effects (&lt;1/10 and &ge;1/100):&nbsp;</strong></p><ul><li>Increased appetite.&nbsp;</li><li>Feeling of elation, confusion, disorientation, changes in sexual interest, irritability.&nbsp;</li><li>Disturbance in attention, clumsiness, memory impairment, tremor, difficulty with speaking, tingling feeling, sedation, lethargy, insomnia, fatigue.&nbsp;</li><li>Blurred vision, double vision.&nbsp;</li><li>Vertigo, problems with balance.&nbsp;</li><li>Dry mouth, constipation, vomiting, and flatulence.&nbsp;</li><li>Difficulties with erection.&nbsp;</li><li>Swelling of the body including extremities.&nbsp;</li><li>Feeling drunk, abnormal style of walking.&nbsp;</li><li>Weight gain.&nbsp;</li></ul><p><strong>Uncommon side-effects (&lt;1/100 and &ge;1/1000):&nbsp;</strong></p><ul><li>Loss of appetite, low blood sugar.&nbsp;</li><li>Change in perception of self, restlessness, depression,&nbsp;agitation, mood swings, difficulty finding words, loss of memory, hallucinations, abnormal dreams, panic attacks, apathy, feeling&nbsp;abnormal, problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation.</li><li>Difficulty with thinking, numbness, changes in eyesight, unusual eye movement, jerky movements, reduced reflexes, increased activity, dizziness on standing, sensitive skin, loss of taste, burning sensation, tremor on movement, decreased -consciousness, fainting, increased sensitivity to noise.&nbsp;</li><li>Dry eyes, eye swelling, eye pain, weak eyes, and watery eyes.&nbsp;</li><li>Heart rhythm disturbances, increased heart rate, low blood&nbsp;pressure, high blood pressure.&nbsp;</li><li>Flushing, hot flushes.&nbsp;</li><li>Difficulty breathing, sore throat, dry nose.&nbsp;</li><li>Swollen abdomen, increased saliva production, heartburn, numb&nbsp;around mouth.&nbsp;</li><li>Sweating, rash, chills.&nbsp;</li><li>Muscle twitching, joint swelling, muscle cramp, muscle stiffness,&nbsp;pain including muscle pain, joint pain, back pain, pain in limb.&nbsp;</li><li>Difficulty with or painful urination, incontinence.&nbsp;</li><li>Weakness, fall, thirst, chest tightness.&nbsp;</li><li>Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine amino transferase increased,&nbsp;aspartate aminotransferase increased, platelet count decreased).&nbsp;</li></ul><p><strong>Rare side-effects (&lt;1/1000):&nbsp;</strong></p><ul><li>Changes in heart beat.&nbsp;</li><li>Coldness of hands and feet.&nbsp;</li><li>Cough, nasal congestion, runny nose, nose bleed, snoring.</li><li>Abnormal sense of smell, changes in vision including tunnel vision, swinging vision, altered perception of depth, flashes of light, visual brightness.&nbsp;</li><li>Dilated pupils, cross eyes, eye irritation.&nbsp;</li><li>Fever, ccld sweat, tightness of the throat.&nbsp;</li><li>Inflammation of the pancreas.&nbsp;</li><li>Difficulty in swallowing.&nbsp;</li><li>Slow or reduced movement of the body.&nbsp;</li><li>Difficulty with writing properly.&nbsp;</li><li>Hives.&nbsp;</li><li>Increased fluid in the abdomen.&nbsp;</li><li>Muscle damage.&nbsp;</li><li>Neck pain.&nbsp;</li><li>Breast pain, breast discharge, abnormal breast growth, painful or interrupted menstrual periods.&nbsp;</li><li>High blood sugar.&nbsp;</li><li>Weight loss.&nbsp;</li><li>Elevated mood.&nbsp;</li><li>Kidney failure, reduced urine volume.&nbsp;</li><li>Changes in blood test results (decrease in blood potassium, increase in blood creatinine, decrease in white blood cell count including neutrophils).&nbsp;</li><li>Inappropriate behavior.&nbsp;</li></ul><p>Additional reactions reported from post marketing experience include heart failure, changes in the recording of electrical changes (ECG) in the heart which ccrrespond to heart rhythm disturbances, fluid in the lungs, loss of consciousness, convulsions, hypersensitivity and allergic reactions (which may include swollen face, swollen tongue, difficulty breathing, itchiness, inflammation of the eyes (keratitis), vision loss and a serious skin reaction characterized by rash, blisters, peeling skin and pain), mental impairment, aggression, urinary retention, diarrhea, headache, nausea, and feeling unwell. <strong>If you experience swollen face or tongue or if your skin turns red and starts to blister or peel you should seek immediate medical advice.&nbsp;</strong><br />Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together.&nbsp;<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30&deg;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance: </strong>pregabalin. Each hard capsule ccntains 75 mg, 150 mg or 300 mg pregabalin.&nbsp;<br /><strong>The other ingredients:</strong> Lactose, Starch, Purified Talc, Gelatin, ntanium Dioxide (E171 ).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Neurogab Opaque white to off-white capsules, Neurogab is available as 30 capsules pack sizes. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DAMMAM PHARMA&nbsp;</strong><br />Dammam Pharmaceutical Plant&nbsp;<br />Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2014.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي <strong>نيوروجاب</strong> إلى مجموعة من الأدوية تستخدم للبالغين في حالة علاج الصرع، ألم الاعتلال العصبي واضطراب القلق المتعمم.</p><p><strong>ألم الاعتلال العصبي الطرفي والمركزي:</strong> إن <strong>نيووروجاب</strong> يستخدم في علاج حالات الألم المستمر الناتج عن تلف في الأعصاب. إذ أن هناك الكثير من الأسباب التي قد تؤدي إلى حصول ألم الاعتلال العصبي الطرفي مثل السكري أو الهريس النطاقي. ويشعر المريض بألم يمكن وصفه بأنه حار، حارق، نابض، بارق، طعن، حاد، تشنج، وجع، وخز، تنمل، إبر أو دبابيس. كما أنه قد يصاحب ألم الاعتلال العصبي الطرفي والمركزي اضطرابات في المزاج، عدم انتظام في النوم، التعب (الإرهاق)، كما أنه قد يؤثر على وظائف المريض الجسدية والنفسية كما أنه يؤثر على نوعية الحياة بشكل عام عند المريض.</p><p><strong>الصرع:</strong> يمكن استخدام <strong>نيوروجاب</strong> لعلاج شكل محدد من الصرع (نوبات الصرع الجزئية بتعميم ناجم عنه أو بدونه) عند البالغين. إن طبيبك سوف يقوم بوصفه لك كعلاج إضافي للعلاج الذي تتناوله حاليا في حالة أن العلاج الحالي لنوبات الصرع التي تعاني منها غير كافي للسيطرة عليها. إن <strong>نيوروجاب</strong> لا يصرف وحده كعلاج لهذه الحالات، بل يتوجب دائما تناوله بمصاحبة أدوية علاج نوبات الصرع الأخرى.</p><p><strong>اضطراب القلق المتعمم:</strong> كما أن <strong>نيوروجاب</strong> يوصف كعلاج لحالات اضطرابات القلق المتعمم. تتمثل أعراض اضطرابات القلق المتعمم بزيادة القلق والتوتر واستمراره لفترات طويلة يصعب السيطرة عليها. كما أن اضطرابات القلق المتعمم قد تسبب أيضا التململ والإحساس بالضيق أو العصبية، الشعور بالتعب أو الإرهاق بسهولة، صعوبة التركيز أو النسيان، سرعة التهيج، وجود تشنج عضلي أو عدم انتظام النوم. وهذه الأعراض تختلف عن الضغوط والتوترات الناتجة عن الحياة اليومية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع تناول نيوروجاب</strong></p><p>إذا كنت تعاني من فرط التحسس (التآق) من مادة بريجابالين أو لأي من مكونات <strong>نيوروجاب</strong> الأخرى.</p><p><strong>الاحتياطات عند تناول نيوروجاب</strong></p><p>لم تتم دراسة أمان وفعالية بريجابالين على الأطفال والمراهقين (تحت سن 18 سنة)، وعليه يجب تجنب إعطاء بريجابالين للمرضى ضمن هذه الفئة العمرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سجل في حالة بعض المرضى لدى تناولهم مادة بريجابالين حدوث أعراض تدل على حدوث تفاعل فرط تحسس. شملت هذه الأعراض تورم في الوجه، الشفاه، اللسان، والحنجرة، كما سجل ظهور طفح جلدي منتشر، في حالة ظهور مثل هذه الأعراض عليك، يجب عليك مراجعة طبيبك فورا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يصاحب تناول <strong>نيوروجاب </strong>شعور بالدوخة والنعاس والتي<strong> </strong>قد تزيد من احتمالية<strong> </strong>الإصابة نتيجة السقوط في حالة المرضى كبار السن. لذلك يجب أن تتوخى الحذر لحين التعود على أي تأثير قد يصاحب هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب تناول <strong>نيوروجاب</strong> حدوث ضبابية في الرؤية أو فقدان للإبصار، أو أي تغير في القدرة على الإبصار، معظم هذه التغيرات يكون مؤقتا. إذا شعرت بأي تغير في قدرتك على الإبصار أثناء تناول <strong>نيوروجاب</strong> يتوجب عليك مراجعة طبيبك فورا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة بعض مرضى السكري الذين قد تحدث زيادة في الوزن لديهم نتيجة تناول <strong>نيوروجاب</strong> قد يحتاجون إلى إجراء تعديل في أدويتهم المخفضة للسكر في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تزداد احتمالية ظهور بعض الأعراض الجانبية مثل النعاس في حالة المرضى الذين يعانون من إصابات في النخاع الشوكي بسبب تناولهم أدوية أخرى مثل مضادات الألم والتشنج، التي تكون تأثيراتها الجانبية مماثلة لتأثيرات <strong>نيوروجاب</strong>، لذلك تزداد حدة هذه الأعراض عند تناول <strong>نيوروجاب</strong> مع هذه الأدوية بشكل متزامن.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>سجل حدوث حالات قصور في القلب عند تناول مادة بريجابالين في حالة بعض مرضى كبار السن والذين يعانون من اضطرابات قلبية وعائية. <strong>لذا يجب عليك أن تخبر طبيبك العالج قبل تناول هذا الدواء إذا كنت تعاني من مشاكل في القلب.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورد في بعض التقارير حدوث قصور في وظائف الكلى عند بعض المرضى لدى تناولهم مادة بريجابالين. إذ لاحظت حدوث شح في التبول لديك أثناء تناول <strong>نيوروجاب</strong>، يجب عليك أن تخبر طبيبك طالما أن التبول يعود لطبيعته عند التوقف عن <strong>نيوروجاب.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سجل في حالات محدودة لدى بعض المرضى الذين يعالجون بأدوية للصرع مشابهة <strong>لنيوروجاب </strong>تكون أفكار لديهم بقتل أو إيذاء أنفسهم. إذا تكونت لديك مثل هذه الأفكار في أي وقت قم باستشارة طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تناول <strong>نيوروجاب</strong> بشكل متزامن مع أدوية أخرى تسبب الإصابة بالإمساك (مثل بعض أنواع أدوية الألم) فمن المحتمل حدوث مشاكل في الجهاز الهضمي (مثل الإمساك، انسداد أو شلل الأمعاء). أخبر طبيبك في حالة إصابتك بالإمساك، خصوصا إذا كنت ممن يصابون بمشكلة الإمساك بشكل متكرر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تناول هذا الدواء يتوجب عليك إخبار طبيبك إذا كان قد سبق أن أصبت بالإدمان على الكحول أو الأدوية. كما يجب عليك أن تخبر طبيبك إذا شعرت أنك محتاج لدواء أكثر من الموصوف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سجل في بعض الحالات حدوث تشنجات أثناء تناول بريجابالين أو خلال فترة قصيرة بعد التوقف عن تناوله. إذا أصبت بمثل هذه التشنجات قم باستشارة طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سجل في بعض الحالات حدوث انخفاض في وظائف الدماغ (اعتلال دماغي) عند تناول بريجابالين في حالة بعض المرضى الذين يعانون من مشاكل صحية أخرى، قبل تناول هذا الدواء يتوجب عليك إخبار طبيبك إذا كان لديك تاريخ مرضي لحدوث مشاكل صحية خطيرة، يشمل ذلك أمراض الكبد والكلى.</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا الدواء مع أي أدوية أو أعشاب أو مكملات غذائية:</strong></p><p dir="RTL">قبل تناول أي دواء آخر مع <strong>نيوروجاب </strong>يتوجب عليك إخبار طبيبك بذلك. فضلا أخبر الطبيب أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرا أي دواء آخر يشمل ذلك الأدوية التي تصرف بدون وصفة.</p><p dir="RTL">قد تحدث بعض التداخلات الدوائية وذلك عند تناول <strong>نيوروجاب </strong>بشكل متزامن مع بعض الأدوية؛ حيث أن تناول <strong>نيوروجاب </strong>مع هذه الأدوية قد يؤدي إلى زيادة التأثيرات الجانبية الناتجة عن تناول هذه الأدوية، وقد يشمل ذلك حدوث قصور تنفسي وغيبوبة. كما أن حدة الدوخة والنعاس وقلة التركيز الناتجة عن <strong>نيوروجاب </strong>قد تزداد عند تناول <strong>نيوروجاب </strong>مع أدوية تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسيكودون (يستخدم كمضاد الألم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لورازيبام (يستخدم لعلاج القلق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكحول.</p><p dir="RTL">يمكن استخدام <strong>نيوروجاب </strong>بشكل متزامن مع أدوية منع الحمل التي يتم إعطائها عن طريق الفم.</p><p dir="RTL"><strong>تناول نيوروجاب مع الطعام والشراب:</strong></p><p dir="RTL">يمكن تناول كبسولات <strong>نيوروجاب </strong>مع الطعام أو بدونه.</p><p dir="RTL">يوصى بعدم تناول الكحول أثناء تناول <strong>نيوروجاب.</strong></p><p dir="RTL"><strong>الحمل والرضاعة:</strong></p><p dir="RTL">استشيري طبيبك أو لصيدلي قبل تناول أي دواء أثناء الحمل أو الرضاعة.</p><p dir="RTL">يجب عدم تناول <strong>نيوروجاب </strong>أثناء الحمل مالم يوصي طبيبك بخلاف ذلك.</p><p dir="RTL">يجب استخدام موانع حمل فعالة أثناء تناول <strong>نيوروجاب </strong>في حالة النساء الذين في سن الإنجاب.</p><p dir="RTL">استشيري طبيبك على الفور إذا أصبحت حاملا، أو كنت تفكرين أو تخططين للحمل أثناء تناول <strong>نيوروجاب.</strong></p><p dir="RTL">لا ينصح أن تقومي بإرضاع طفلك أثناء تناول <strong>نيوروجاب</strong> حيث أنه لا توجد معلومات إلى الآن حول إفراو مادة بيجابالين في حليب الأم. استشيري طبيبك أو الصيدلي قبل تناول أي دواء أثناء الرضاعة.</p><p dir="RTL"><strong>تأثير</strong> <strong>نيوروجاب على القيادة واستعمال الآلات:</strong></p><p dir="RTL">قد يسبب تناول <strong>نيوروجاب </strong>حدوث دوخة، نعاس وقلة في التركيز. لذا يتوجب عليك تجنب القيادة، استعمال الآلات أو القيام بأي عمل فيه خطورة إلى أن تتأكد من أن هذا الدواء لا يحدث مثل هذه التأثيرات عندك.</p><p dir="RTL"><strong>معلومة هامة حول بعض مكونات نيوروجاب:</strong></p><p dir="RTL">يحتوي <strong>نيوروجاب</strong> على لاكتوز. استشر طبيبك قبل تناول هذا الدواء، إذا كان قد أخبرك سابقا بأنك تعاني من مشكلة عدم التحمل لبعض أنواع السكر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما يتوجب عليك تناول<strong> نيوروجاب </strong>حسب الجرعة الموصوفة من قبل طبيبك، لذا يتوجب عليك استشارة طبيبك أو الصيدلي في حالة عدم تأكدك من الجرعة.</p><p dir="RTL">إن طبيبك سوف يقوم بتحديد الجرعة المناسبة لك.</p><p dir="RTL"><strong>ألم الاعتلال العصبي المركزي والطرفي، الصرع، اضطراب القلق المتعمم:</strong></p><p dir="RTL">تناول عدد الكبسولات تماما كمل وصفه الطبيب لك.</p><p dir="RTL">إن الجرعة سيتم تحديدها بما يتناسب مع حالتك وتتراوح عادة بين 150 ملجم و600 ملجم يوميا.</p><p dir="RTL">إن طبيبك سوف يخبرك أن تتناول <strong>نيوروجاب </strong>إما مرتين أو ثلاث مرات يوميا. في حالة أنه أخبرك أن تتناولها مرتين، تناول كبسولة <strong>نيوروجاب </strong>واحدة صباحا وواحدة مساء يوميا وفي نفس الوقت تقريبا.</p><p dir="RTL">في حالة أنه قد وصفه لك ثلاث مراث يوميا تناول كبسولة <strong>نيوروجاب </strong>واحدة صباحا وواحدة بعد الظهر والثالثة عند مساء يوميا وفي نفس الوقت تقريبا.</p><p dir="RTL">إذا شعرت أن تأثير <strong>نيوروجاب </strong>أقوى أو أضعف من المطلوب، أخبر طبيبك أو الصيدلي.</p><p dir="RTL">إذا كنت مريضا كبير السن (أكبر من65سنة)، تناول <strong>نيوروجاب</strong> بشكل اعتيادي إلا إذا كنت تعاني من مشاكل في الكلى.</p><p dir="RTL">في حالة المرضى الذين يعانون من مشاكل في الكلى قد يصف الطبيب هذا الدواء بنظام أو جرعة مختلفة عن الجرعات الاعتيادية.</p><p dir="RTL">إبلع الكبسولة كاملة كما هي مع كمية كافية من الماء.</p><p dir="RTL">استمر بتناول <strong>نيوروجاب</strong> كما وصف لك إلى أن يطلب منك الطبيب التوقف عن تناوله.</p><p dir="RTL"><strong>الجرعة الزائدة من نيوروجاب</strong></p><p dir="RTL">اتصل بطبيبك أو اذهب إلى أقرب وحدة طوارئ في الحال. خذ علبة كبسولات <strong>نيوروجاب</strong> معك. قد تشعر بالنعاس، الارتباك، الهياج وعدم الارتياح عند تناولك جرعة زائدة من <strong>نيوروجاب.</strong></p><p dir="RTL"><strong>نسيان تناول جرعة من نيوروجاب</strong></p><p dir="RTL">من المهم جدا تناول كبسولات <strong>نيوروجاب</strong> بانتظام وفي نفس الوقت يوميا. في حالة نسيان جرعة من <strong>نيوروجاب</strong> تناول هذه الجرعة فور تذكرها إلا إذا كان ذلك في وقت الجرعة التالية في هذه الحالة خذ الجرعة التالية فقط وأكمل كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>التوقف عن تناول نيوروجاب</strong></p><p dir="RTL">لا تتوقف عن تناول <strong>نيوروجاب </strong>مالم يطلب طبيبك منك ذلك. وفي هذه الحالة يتوجب عليك التوقف عن تناول <strong>نيوروجاب</strong> بشكل تدريجي على مدى أسبوع واحد كحد أدنى. إذا كانت لديك أية استفسارات إضافية حول هذا الدواء فضلا استشر طبيبك أو الصيدلي.</p><p dir="RTL">بعد التوقف عن العلاج سواء أكان العلاج لفترات طويلة أو قصيرة بواسطة بريجابالين، قد تصاب ببعض الأعراض الجانبية التي تشتمل على: اضطراب في النوم، الصداع، الغثيان، الشعور بالتوتر، الاسهال، أعراض شبيهة بالزكام، التشنجات، العصبية، الاكتئاب، الألم، التعرق، والدوخة. ولا توجد معلومات إلى الآن عما إذا كانت هذه الأعراض ستكون أكثر حدوثا أو شدة إذا كان المريض قد تناول بريجابالين لفترات طويلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في جميع الأدوية، فإن تناول <strong>نيوروجاب</strong> قد يصاحبه ظهور بعض الأعراض الجانبية والتي ليس بالضرورة أن تظهر عند كل من يتناول <strong>نيوروجاب.</strong></p><p dir="RTL"><strong>&nbsp;أعراض جانبية شائعة جدا (&ge;1/10):&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، التعب.</p><p dir="RTL"><strong>أعراض جانبية شائعة (</strong><strong>&lt;</strong><strong>1/10 و </strong><strong>&ge;</strong><strong>1/100):</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>زيادة الشهية.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الإحساس بالنشوة، الارتباك، التوهان، اضطرابات في الاهتمام الجنسي، التهيج.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>اختلال في التركيز والمهارة، ضعف الذاكرة، الرعاش، صعوبة في الكلام، الإحساس بالوخز، التخدير والخمول، الأرق، التعب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضبابية الرؤية، ازدواج الرؤية.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الدوار، مشاكل في التوازن.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>جفاف الفم، الإمساك، القيء، والانتفاخ.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة الانتصاب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورم الجسم يشمل ذلك الأطراف.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>شعور بالثمل، اختلال طريقة المشي.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>زيادة في الوزن.</p><p dir="RTL"><strong>أعراض جانبية غير شائعة (</strong><strong>&lt;</strong><strong>1/100 و </strong><strong>&ge;</strong><strong>1/1000):</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فقدان الشهية، انخفاض سكر الدم.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تغير النظرة إلى الذات، عدم الارتياح، الاكتئاب، هياج، تأرجح المزاج، صعوبة إيجاد الكلمات، فقدان الذاكرة، هلوسة، أحلام غير طبيعية، الشعور بالهلع، خمول، الإحساس بالاختلال، اضطرابات في الوظائف الجنسية تشمل عدم القدرة على الوصول إلى هزة الجماع، تأخر القذف.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;صعوبة في التفكير، تنمل، تغيرات في البصر، حركة غير طبيعية للعين، حركات نفضية، انخفاض المنعكسات، زيادة في النشاط، دوخة عند الوقوف، تحسس الجلد، فقدان حاسة التذوق، إحساس بالحرقان، رجفة في الحركة، انخفاض الوعي، إغماء، زيادة الحساسية تجاه الضوضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العينين، تورم العينين، ألم العينين، ضعف العينين، والتدمع.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;اضطراب نظم القلب، زيادة سرعة القلب، انخفاض ضغط الدم، ارتفاع ضغط الدم.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>احمرار الوجه، توردات ساخنة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة في التنفس، التهاب الحلق، جفاف الأنف.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورم البطن، زيادة افراز اللعاب، حرقة الفؤاد، تخدر حول الفم.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التعرق، طفح، القشعريرة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتعاص العضلات، تورم المفاصل، تشنج عضلي، تيبس عضلي، ألم يشمل ألم العضلات، ألم الظهر، ألم في الأطراف.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة أو ألم عند التبول، عسر التبول.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضعف، سقوط، عطش، ضيق في الصدر.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تغيرات في نتائج قيم اختبارات الدم ووظائف الكبد (زيادة فسفوكيناز كرياتين الدم، زيادة ألانين أمينو ترانسفيريز، زيادة أسبارتيت أمينو ترانسفيريز، نقص الصفيحات الدموية).</p><p dir="RTL"><strong>أعراض جانبية نادرة (</strong><strong>&lt;</strong><strong>1 /1000)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في ضربة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برودة الأيدي والأقدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال، احتقان الأنف، سيلات الأنف، الرعاف، شخير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال في حاسة الشم، اضطراب في الإبصار بما في ذلك؛ الرؤية النفقية، تذبذب الإبصار، تحسس العمق البصري المتغير، وهج الضوء، بهر البصر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الحدقة، حول إنسي، تهيج العينين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، العرق البارد، ضيق الحنجرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة النشاط أو ضعف الحركة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الكتابة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السوائل في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انحلال العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عنقي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الثدي، إفراز الثدي، تضخم الثدي، ألم أو اضطراب في الدورة الشهرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى سكر الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع المزاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي، شح البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج قيم اختبارات الدم (نقص بوتاسيوم الدم، زيادة كرياتينين الدم، نقص عدد كريات الدم البيضاء بما في ذلك العدلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب السلوك.</p><p dir="RTL">هذا وقد سجلت آثار جانبية أخرى بعد أن تم استخدام بريجابالين على المرضى تشمل هذه الآثار الجانبية قصور القلب، تغيرات في التخطيط الكهربائي للقلب (ECG) مما يدل على حدوث اختلالات في نظم القلب، الاستسقاء الرئوي، فقدان الوعي، التشنجات، تفاعلات فرط التحسس التأق (قد تشمل هذه التفاعلات على تورم الوجه، تورم اللسان، صعوبة التنفس، الحكة، تهيج العينين (التهاب القرنية)، فقدان الإبصار، وحدوث تفاعل جلدي خطير يتميز بحدوث طفح، نفط، تقشر الجلد وألم)، اعتلال عقلي، عنف، حصر بول، إسهال، صداع، غثيان، وإحساس بالمرض.</p><p dir="RTL"><strong>في حالة إصابتك بتورم في الوجه أو اللسان، أو تغير لون جلدك إلى الأحمر وظهرت نفط عليه وبدأ يتقشر يجب عليك مراجعة الطبيب فورا.</strong></p><p dir="RTL">قد تزداد احتمالية ظهور بعض الأعراض الجانبية مثل النعاس في حالة المرضى الذين يعانون من إصابات في النخاع الشوكي بسبب تناولهم أدوية أخرى مثل مضادات الألم والتشنج، والتي تكون تأثيراتها الجانبية مثل التأثيرات بريجابالين، لذلك تزداد حدة هذه الأعراض عند تناول <strong>نيوروجاب</strong> مع هذه الأدوية بشكل متزامن.</p><p dir="RTL">إذا ازدادت شدة إحدى هذه الأعراض، أو أصبت بأية أعراض جانبية أخرى لم تذكر في هذه النشرة، أخبر طبيبك المعالج أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ في درجة حرارة أقل من 30 درجة مئوية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة الفعالة:</strong>&nbsp;بريجابالين. كل كبسولة صلبة تحتوي على 75 ملجم، 150 ملجم، 300 ملجم بريجابالين.&nbsp;</p><p><strong>المكونات الأخرى:&nbsp;</strong>لاكتوز، نشا، تالك نقي، جيلاتين، ثاني أكسيد التيتانيوم (&nbsp;E171).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">إن&nbsp;<strong>نيوروجاب</strong>&nbsp;متوافر على شكل كبسولات لونها يتراوح بين اللون الأبيض الكامد إلى اللون الأبيض الفاتح في عبوات سعة 30 كبسولة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الدمام فارما</strong></p><p>مصنع الأدوية بالدمام&nbsp;</p><p>المملكة العربية السعودية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2014.  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Neurogab 75mg Capsule
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 75 mg of pregabalin.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neuropathic pain:</u></p><p>Neurogab is indicated for the treatment of peripheral and central neuropathic pain in adults.</p><p>&nbsp;</p><p><u>E</u><u>p</u><u>ilepsy;</u></p><p>Neurogab is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.</p><p>&nbsp;</p><p><u>Generalized Anxiety Disorder:</u></p><p>Neurogab is indicated for the treatment of Generalized Anxiety Disorder</p><p>(GAD) in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dose range is 150 to 600 mg per day given in either two or three divided doses.</p><p>&nbsp;</p><p>Neuropathic pain</p><p>Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.</p><p>&nbsp;</p><p><u>E</u><u>p</u><u>ileps</u><u>y</u></p><p>Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses.</p><p>Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p>&nbsp;</p><p><u>Generalized Anxiety Disorder</u></p><p>The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.</p><p>Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p>&nbsp;</p><p><u>Discontinuation of pregabalin</u></p><p>In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Sp</u><u>ec</u><u>i</u><u>al populations</u></p><p>Pediatric Use:</p><p>The safety and efficacy of Pregabalin in children below the age of 12 years and in adolescents</p><p>(12-17 years of age) have not been established. No data are available.</p><p>&nbsp;</p><p>Geriatric Use (over 65 years of age):</p><p>Elderly patients may require a dose reduction of pregabalin due to a decreased renal function</p><p>(see patients with renal impairment).</p><p>&nbsp;</p><p>Patient with renal impairment:</p><p>Pregabalin &nbsp;is &nbsp;eliminated &nbsp;from &nbsp;the &nbsp;systemic &nbsp;circulation &nbsp;primarily &nbsp;by &nbsp;renal &nbsp;excretion &nbsp;as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance (see section&nbsp; &nbsp;5.2),&nbsp; &nbsp;dose&nbsp; &nbsp;reduction&nbsp; &nbsp;in&nbsp; &nbsp;patients&nbsp; &nbsp;with&nbsp; &nbsp;compromised&nbsp; &nbsp;renal&nbsp; &nbsp;function&nbsp; &nbsp;must&nbsp; &nbsp;be individualized &nbsp;according &nbsp;to creatinine &nbsp;clearance &nbsp;(CLcr), as indicated&nbsp; in Table 1 determined using the following formula:</p><p><br /><img src="data:image/png;base64,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" alt="" width="571" height="78" vspace="0" hspace="0" border="0" style="width:571px;height:78px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4-hour haemodialysis treatment (see Table 1).</p><p>Table 1. Pregabalin dose adjustment based on renal function:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance</p><p>(CLcr ) (mL/mi)</p></td><td colspan="2" style="vertical-align:top"><p>Total pregabalin daily dose *</p><p>Dose regimen</p></td><td style="vertical-align:top"><p>Dose regimen</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Starting dose</p><p>(mg/day)</p></td><td style="vertical-align:top"><p>Maximum dose</p><p>(mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge;60</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr><tr><td style="vertical-align:top"><p>&ge;30 - &lt;60</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr><tr><td style="vertical-align:top"><p>&ge;15 - &lt;30</p></td><td style="vertical-align:top"><p>25 &ndash; 50</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>Once Daily or BID</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 15</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>Once Daily</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Supplementary dosage following haemodialysis (mg)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>Single dose+</p></td></tr></tbody></table><p>&nbsp;</p><p>TID = Three divided doses</p><p>BID = Two divided doses</p><p>* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose</p><p>+ Supplementary dose is a single additional dose.</p><p>&nbsp;</p><p>Use in patients with hepatic impairment</p><p>No dose adjustment is required for patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>Method &nbsp;of administration</p><p>Pregabalin may be taken with or without food.</p><p>NEUROGAB is for oral use only.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Diabetic patients</u></p><p>In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycemic medicinal products.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>There have been reports in the post marketing experience of hypersensitivity reactions, including&nbsp; &nbsp;cases&nbsp; &nbsp;of &nbsp;angioedema.&nbsp; &nbsp;Pregabalin&nbsp; &nbsp;should&nbsp; &nbsp;be&nbsp;&nbsp; discontinued&nbsp; &nbsp;immediately&nbsp; &nbsp;if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.</p><p>&nbsp;</p><p><u>Dizziness, somnolence, loss of consciousness, confusion, and mental impairment</u></p><p>Pregabalin &nbsp;treatment &nbsp;has &nbsp;been&nbsp; associated &nbsp;with&nbsp; dizziness &nbsp;and &nbsp;somnolence, &nbsp;which &nbsp;could increase the occurrence of accidental injury (fall) in the elderly population. There have also been post-marketing reports of loss of consciousness, confusion and mental impairment. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product.</p><p>&nbsp;</p><p><u>Vision-related effects</u></p><p>In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than did patients treated with placebo which resolved in a majority of cases with continued dosing. In the clinical studies where ophthalmologic testing was conducted, the incidence of visual acuity reduction &nbsp;and visual field changes was greater in pregabalin- treated patients than in placebo-treated patients; the incidence of fundoscopic changes was greater in placebo-treated patients (see section 5.1).</p><p>In &nbsp;the &nbsp;post-marketing &nbsp;experience, &nbsp;visual &nbsp;adverse &nbsp;reactions &nbsp;have &nbsp;also &nbsp;been &nbsp;reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient. Discontinuation&nbsp; of pregabalin may result in resolution or improvement of these visual symptoms.</p><p>&nbsp;</p><p><u>R</u><u>e</u><u>n</u><u>a</u><u>l failure</u></p><p>Cases of renal failure have been reported and in some cases discontinuation of pregabalin did show reversibility of this adverse reaction.</p><p>&nbsp;</p><p><u>W</u><u>ithdrawal of concomitant antiepileptic medicinal products</u></p><p>There &nbsp;are &nbsp;insufficient &nbsp;data &nbsp;for &nbsp;the &nbsp;withdrawal &nbsp;of &nbsp;concomitant &nbsp;antiepileptic &nbsp;medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.</p><p>&nbsp;</p><p><u>W</u><u>ithdrawal symptoms</u></p><p>After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms&nbsp;&nbsp; have &nbsp;been &nbsp;observed &nbsp;in &nbsp;some &nbsp;patients. &nbsp;The &nbsp;following &nbsp;events &nbsp;have &nbsp;been mentioned: insomnia, headache, nausea, anxiety, diarrhea, flu syndrome, nervousness, depression, pain, convulsion, hyperhidrosis and dizziness. The patient should be informed about this at the start of the treatment. Convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use or shortly after discontinuing pregabalin. Concerning discontinuation of long-term treatment of pregabalin there are no data of the incidence and severity of withdrawal symptoms in relation to duration of use and dose of pregabalin.</p><p>&nbsp;</p><p><u>C</u><u>ongestive heart failure</u></p><p>There &nbsp;have &nbsp;been &nbsp;post-marketing &nbsp;reports &nbsp;of &nbsp;congestive &nbsp;heart &nbsp;failure &nbsp;in &nbsp;some &nbsp;patients receiving pregabalin.</p><p>These &nbsp;reactions &nbsp;are mostly &nbsp;seen &nbsp;in elderly &nbsp;cardiovascular &nbsp;compromised &nbsp;patients &nbsp;during</p><p>pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.</p><p>&nbsp;</p><p><u>T</u><u>r</u><u>e</u><u>a</u><u>tment of central neuropathic pain due to spinal cord injury</u></p><p>In the treatment &nbsp;of central &nbsp;neuropathic &nbsp;pain &nbsp;due to spinal &nbsp;cord &nbsp;injury the incidence &nbsp;of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased. This may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity agents) needed for this condition. This should be considered when prescribing pregabalin in this condition.</p><p>&nbsp;</p><p><u>S</u><u>uicidal ideation and behavior</u></p><p>Suicidal ideation and behavior&nbsp; have been reported &nbsp;in patients &nbsp;treated with anti-epileptic agents in several indications. A meta-analysis of randomized placebo controlled studies of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behavior. The &nbsp;mechanism &nbsp;of &nbsp;this &nbsp;risk &nbsp;is &nbsp;not &nbsp;known &nbsp;and &nbsp;the &nbsp;available &nbsp;data &nbsp;do &nbsp;not &nbsp;exclude &nbsp;the possibility of an increased risk for pregabalin.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviors and</p><p>appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behavior emerge.</p><p>&nbsp;</p><p><u>R</u><u>e</u><u>duced lower gastrointestinal tract function</u></p><p>There are post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, constipation) when pregabalin was co- administered &nbsp;with &nbsp;medications &nbsp;that &nbsp;have &nbsp;the potential &nbsp;to produce &nbsp;constipation, &nbsp;such &nbsp;as opioid analgesics. When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).</p><p>&nbsp;</p><p><u>Abuse potential</u></p><p>Cases of abuse have been reported. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalin abuse.</p><p>&nbsp;</p><p><u>E</u><u>ncephalopathy</u></p><p>Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.</p><p><u>Respiratory Depression</u></p><p>Pregabalin has been associated with serious, life-threatening, and fatal respiratory depression. The risk may be increased with the concomitant use of opioids and other central nervous system (CNS) depressants, and with conditions such as chronic obstructive pulmonary disease. The elderly are also at higher risk. Health care providers should start pregabalin at the lowest dose and monitor patients for symptoms of respiratory depression and sedation when co-prescribing pregabalin with an opioid or other CNS depressants (eg, benzodiazepines). Patients with underlying respiratory disease and elderly patients are also at increased risk and should be managed similarly.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>L</u><u>a</u><u>c</u><u>tose intolerance</u></p><p>Neurogab&nbsp; &nbsp;contains&nbsp; &nbsp;lactose&nbsp; &nbsp;monohydrate.&nbsp; &nbsp;Patients&nbsp; &nbsp;with &nbsp;rare &nbsp;hereditary&nbsp; &nbsp;problems&nbsp; &nbsp;of galactose &nbsp;intolerance, &nbsp;the &nbsp;Lapp &nbsp;lactase &nbsp;deficiency &nbsp;or &nbsp;glucose-galactose &nbsp;malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (&lt;2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.</p><p>&nbsp;</p><p><u>I</u><u>n vivo studies and population pharmacokinetic analysis</u></p><p>Accordingly, in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.</p><p>&nbsp;</p><p><u>Oral contraceptives, norethisterone and/or ethinyl oestradiol</u></p><p>Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>E</u><u>t</u><u>hanol, lorazepam, oxycodone</u></p><p>Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. In the post marketing experience, there are &nbsp;reports &nbsp;of &nbsp;respiratory &nbsp;failure &nbsp;and &nbsp;coma &nbsp;in&nbsp; patients &nbsp;taking &nbsp;pregabalin &nbsp;and &nbsp;other &nbsp;CNS depressant &nbsp;medicinal &nbsp;products. &nbsp;Pregabalin &nbsp;appears &nbsp;to &nbsp;be &nbsp;additive &nbsp;in &nbsp;the &nbsp;impairment &nbsp;of cognitive and gross motor function caused by oxycodone.</p><p>&nbsp;</p><p><u>Opioids and CNS depressants </u></p><p>Serious respiratory depression may occur with pregabalin when co-administered with opioids and CNS depressants such as benzodiazepine. Therefore, monitor for symptoms of respiratory depression and sedation in patients who require concomitant treatment with opioids or CNS depressants.</p><p>&nbsp;</p><p><u>I</u><u>nteractions and the elderly</u></p><p>No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As the potential risk for humans is unknown, effective contraception must be used in women of</p><p>child bearing potential.</p><p>&nbsp;</p><p><u>Pr</u><u>e</u><u>g</u><u>nancy</u></p><p>Pregnancy Category C.</p><p>There are no adequate data from the use of pregabalin in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see 5.3). The potential risk for humans is unknown.</p><p>Pregabalin should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the fetus).</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>e</u><u>a</u><u>s</u><u>t-feeding</u></p><p>It is not known if pregabalin is excreted in the breast milk of humans; however, it is present in the &nbsp;milk &nbsp;of &nbsp;rats. &nbsp;Therefore, &nbsp;breast-feeding&nbsp; &nbsp;is &nbsp;not &nbsp;recommended&nbsp; &nbsp;during &nbsp;treatment &nbsp;with pregabalin.</p><p>&nbsp;</p><p><u>F</u><u>e</u><u>r</u><u>t</u><u>ility</u></p><p>There are no clinical data on the effects of pregabalin on female fertility.</p><p>In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.</p><p>A fertility study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse &nbsp;reproductive &nbsp;and developmental &nbsp;effects. &nbsp;The clinical &nbsp;relevance &nbsp;of these findings is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Neurogab may have minor or moderate influence on the ability to drive and use machines. Pregabalin &nbsp;may cause dizziness &nbsp;and somnolence &nbsp;and therefore &nbsp;may influence &nbsp;the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The &nbsp;pregabalin &nbsp;clinical &nbsp;programme &nbsp;involved &nbsp;over &nbsp;8900 &nbsp;patients &nbsp;who &nbsp;were &nbsp;exposed &nbsp;to pregabalin, of whom over 5600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in intensity.</p><p>In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving &nbsp;pregabalin &nbsp;and &nbsp;5% &nbsp;for &nbsp;patients &nbsp;receiving &nbsp;placebo. &nbsp;The &nbsp;most &nbsp;common &nbsp;adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.</p><p>In the table below all adverse reactions, which occurred at an incidence greater than placebo and &nbsp;in&nbsp; more &nbsp;than &nbsp;one &nbsp;patient, &nbsp;are &nbsp;listed &nbsp;by &nbsp;class &nbsp;and &nbsp;frequency &nbsp;(very &nbsp;common &nbsp;(&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Within &nbsp;each &nbsp;frequency &nbsp;grouping, &nbsp;undesirable &nbsp;effects &nbsp;are &nbsp;presented &nbsp;in &nbsp;order &nbsp;of &nbsp;decreasing</p><p>seriousness.</p><p>The adverse reactions listed may also be associated with the underlying disease and / or concomitant medicinal products.</p><p>In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions &nbsp;in general, &nbsp;CNS adverse &nbsp;reactions &nbsp;and especially &nbsp;somnolence &nbsp;was increased &nbsp;(See</p><p>4.4).</p><p>Additional reactions reported from post-marketing experience are included as Frequency not known in italics in the list below.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>System organ &nbsp;Class</p></td><td style="vertical-align:top"><p>Adverse Drug reactions</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections and infestations</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nasopharyngitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon&nbsp;</p></td><td style="vertical-align:top"><p>Neutropenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>angioedema, allergic reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Appetite increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, hypoglycemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Euphoric mood, confusing, irritability, libido</p><p>decreased, disorientation, insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hallucination, panic attack, restlessness, agitation, depression, depressed mood, elevated mood, aggression, mood swings, depersonalization, word finding difficulty, abnormal dreams, anorgasmia, apathy, libido increased. anorgasmia, apathy.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Disinhibition</p></td></tr><tr><td style="vertical-align:top"><p>Frequency not Known</p></td><td style="vertical-align:top"><p>Loss of consciousness, mental impairment,</p><p>convulsions, headache, malaise</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dizziness, somnolence, headache.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Ataxia, coordination abnormal, tremor,</p><p>dysarthria, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, stupor, myoclonus, loss of consciousness, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, mental impairment, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Convulsions, parosmia, hypokinesia, dysgraphia</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vision blurred, diplopia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia, photopsia, dry eye, lacrimation increased, eye irritation.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vision loss, keratitis, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ear &nbsp;and labyrinth disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperacusis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia, atrioventricular block first degree, sinus bradycardia, congestive heart failure</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>QT prolongation, sinus tachycardia, sinus arrhythmia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension, hypertension, hot flushes, flushing, peripheral coldness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring, nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;Pulmonary oedema, throat tightness,</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, nausea, constipation, diarrhoea, flatulence, abdominal distension, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Ascites, pancreatitis, swollen tongue, dysphagia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash papular, urticaria, hyperhidrosis, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stevens Johnson syndrome, cold sweat</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective &nbsp;tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Joint swelling, myalgia, muscle twitching, neck pain, muscle stiffness.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rhabdomyolysis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urinary incontinence, dysuria.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Renal failure, oliguria, Urinary retention.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Amenorrhoea, breast discharge, breast enlargement, gynaecomastia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Generalisedoedema, face oedema, chest tightness, pain, pyrexia, thirst, chills, asthenia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Investigations</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, blood glucose increased, platelet count decreased, blood creatinine increased, blood potassium decreased, weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>White blood cell count decreased.</p></td></tr></tbody></table><p>&nbsp;</p><p>After &nbsp;discontinuation &nbsp;of &nbsp;short-term &nbsp;and &nbsp;long-term &nbsp;treatment &nbsp;with &nbsp;pregabalin &nbsp;withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhea, flu syndrome, convulsions, nervousness, depression, pain, hyperhidrosis and dizziness. The patient should be informed about this at the start of the treatment.</p><p>Concerning &nbsp;discontinuation &nbsp;of &nbsp;long-term &nbsp;treatment &nbsp;of &nbsp;pregabalin &nbsp;there &nbsp;are &nbsp;no &nbsp;data &nbsp;of &nbsp;the incidence and severity of withdrawal symptoms in relation to duration of use and dose of pregabalin.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_19" o:spid="_x0000_s2050"
 type="#_x0000_t202" style='position:absolute;margin-left:24.3pt;margin-top:-22.8pt;
 width:386.9pt;height:106.65pt;z-index:251658240;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:200;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:200;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox style='mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In overdoses up to 15 g, no unexpected adverse reactions were reported.</p><p>In the post-marketing experience, the most commonly reported adverse reactions observed when pregabalin was taken in overdose included somnolence, confusional state, agitation, and restlessness.</p><p>Treatment of pregabalin overdose should include general supportive measures and may include</p><p>haemodialysis if necessary (see section 4.2 Table 1).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties</p><p>&nbsp;</p><p>- Anatomical Therapeutical Chemical (ATC):</p><p>&nbsp;</p><p>N03AX16.</p><p>&nbsp;</p><p>- Pharmacotherapeutic group:</p><p>&nbsp;</p><p>&nbsp;</p><p>The &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; active &nbsp; substance,&nbsp; &nbsp;pregabalin, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gamma-aminobutyric acid&nbsp; &nbsp;analogue &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ((S)-3- (aminomethyl)-5- methylhexanoic acid).</p><p><u>Me</u><u>c</u><u>h</u><u>a</u><u>nism of action</u></p><p>Pregabalin binds to an auxiliary subunit (&alpha;2-&delta; protein) of voltage-gated calcium channels in the central nervous system, potently displacing [3H]-gabapentin.</p><p><u>C</u><u>linical experience</u></p><p>&nbsp;</p><p>&nbsp;</p><p>Neuropathic pain</p><p>Efficacy has been shown in trials in diabetic neuropathy, &nbsp;post herpetic neuralgia and spinal cord injury.</p><p>Efficacy has not been studied in other models of neuropathic pain.</p><p>Pregabalin has been studied in 10 controlled clinical trials of up to 13 weeks with twice a day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by week 1 and was maintained throughout the treatment period.</p><p>In &nbsp;controlled &nbsp;clinical &nbsp;trials &nbsp;in &nbsp;peripheral &nbsp;neuropathic &nbsp;pain &nbsp;35% &nbsp;of &nbsp;the &nbsp;pregabalin &nbsp;treated patients &nbsp;and &nbsp;18% &nbsp;of &nbsp;the &nbsp;patients &nbsp;on &nbsp;placebo &nbsp;had &nbsp;a&nbsp; 50% &nbsp;improvement &nbsp;in &nbsp;pain &nbsp;score. &nbsp;For patient&rsquo;s not experiencing somnolence, such an improvement was observed in 33% of patients treated &nbsp;with &nbsp;pregabalin &nbsp;and &nbsp;18% &nbsp;of &nbsp;patients &nbsp;on &nbsp;placebo. &nbsp;For &nbsp;patients &nbsp;who &nbsp;experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo.</p><p>In the controlled clinical trial in central neuropathic pain 22% of the Pregabalin treated patients and 7% of the patients on placebo had a 50% improvement in pain score.</p><p>&nbsp;</p><p>&nbsp;</p><p>Epilepsy</p><p>Pregabalin has been studied in 3 controlled clinical trials of 12 week duration with either twice a day dosing (BID) or three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>A reduction in seizure frequency was observed by Week 1.</p><p>&nbsp;</p><p>&nbsp;</p><p>Generalized Anxiety Disorder</p><p>&nbsp;</p><p>&nbsp;</p><p>Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double blind relapse prevention phase of 6 months duration.</p><p>Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A)</p><p>was observed by Week 1.</p><p>In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.</p><p>In controlled &nbsp;trials, a higher proportion &nbsp;of patients &nbsp;treated with pregabalin &nbsp;reported blurred vision &nbsp;than &nbsp;did &nbsp;patients &nbsp;treated &nbsp;with &nbsp;placebo &nbsp;which &nbsp;resolved &nbsp;in&nbsp; a &nbsp;majority &nbsp;of &nbsp;cases &nbsp;with continued dosing. Ophthalmologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. In these patients, visual acuity was reduced in 6.5% of patients treated with pregabalin, and 4.8% of placebo-treated &nbsp;patients. Visual field changes were detected in</p><p>12.4% of pregabalin-treated, and 11.7% of placebo-treated patients. Funduscopic changes were observed in 1.7% of pregabalin-treated and 2.1% of placebo-treated patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain.</p><p>&nbsp;</p><p>Absorption</p><p>Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hour following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be &ge;90% and is independent of dose. Following repeated administration, steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption&nbsp; &nbsp;is &nbsp;decreased&nbsp; &nbsp;when&nbsp; &nbsp;given&nbsp; &nbsp;with&nbsp; &nbsp;food&nbsp; &nbsp;resulting&nbsp; &nbsp;in &nbsp;a &nbsp;decrease&nbsp; &nbsp;in &nbsp;Cmax&nbsp; &nbsp;by approximately&nbsp; &nbsp;25-30%&nbsp; &nbsp;and&nbsp; &nbsp;a&nbsp; &nbsp;delay&nbsp; &nbsp;in&nbsp; &nbsp;tmax&nbsp; &nbsp;to&nbsp; &nbsp;approximately&nbsp; &nbsp;2.5&nbsp; &nbsp;hours.&nbsp; &nbsp;However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.</p><p>&nbsp;</p><p>Distribution</p><p>In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg. Pregabalin is not bound to plasma proteins. Biotransformation</p><p>Pregabalin undergoes negligible metabolism &nbsp;in humans. Following a dose of radiolabelled</p><p>pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. &nbsp;The N-methylated &nbsp;derivative of pregabalin, the major metabolite &nbsp;of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin S-enantiomer to the Renantiomer.</p><p>&nbsp;</p><p>&nbsp;</p><p>Elimination</p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance (see section</p><p>5.2 &nbsp;Renal &nbsp;impairment). &nbsp;Dose &nbsp;adjustment &nbsp;in &nbsp;patients &nbsp;with &nbsp;reduced &nbsp;renal &nbsp;function &nbsp;or undergoing haemodialysis is necessary (see Section 4.2 Table 1).</p><p>&nbsp;</p><p>&nbsp;</p><p>Linearity / non-linearity</p><p>Pregabalin pharmacokinetics are linear over the recommended daily dose range. Inter-subject pharmacokinetic variability for pregabalin is low (&lt;20%). Multiple dose pharmacokinetics are predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.</p><p>&nbsp;</p><p>Pharmacokinetic properties in Special Populations</p><p><u>Gender</u></p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.</p><p>&nbsp;</p><p><u>Re</u><u>nal impairment</u></p><p>Pregabalin clearance is directly proportional to creatinine clearance. In addition, pregabalin is effectively &nbsp;removed &nbsp;from &nbsp;plasma &nbsp;by &nbsp;haemodialysis&nbsp; &nbsp;(following &nbsp;a &nbsp;4 &nbsp;hour &nbsp;haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%). Because renal elimination is the major elimination pathway, dose reduction in patients with renal impairment and dose supplementation following haemodialysis is necessary (see section 4.2 Table 1).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma concentrations.</p><p>&nbsp;</p><p><u>E</u><u>l</u><u>derly (over 65 years of age)</u></p><p>Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age related compromised renal function (see section 4.2 Table 1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In &nbsp;conventional &nbsp;safety &nbsp;pharmacology &nbsp;studies &nbsp;in &nbsp;animals, &nbsp;pregabalin &nbsp;was &nbsp;well-tolerated &nbsp;at clinically relevant doses. In repeated dose toxicity studies in rats and monkeys CNS effects were &nbsp;observed, &nbsp;including &nbsp;hypoactivity, &nbsp;hyperactivity &nbsp;and ataxia. &nbsp;An increased &nbsp;incidence &nbsp;of retinal atrophy commonly observed in aged albino rats was seen after long term exposure to pregabalin at exposures &ge;5 times the mean human exposure at the maximum recommended clinical dose.</p><p>Pregabalin &nbsp;was &nbsp;not &nbsp;teratogenic &nbsp;in &nbsp;mice, &nbsp;rats &nbsp;or &nbsp;rabbits. &nbsp;Fetal &nbsp;toxicity &nbsp;in &nbsp;rats &nbsp;and &nbsp;rabbits</p><p>occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity studies, pregabalin induced offspring developmental toxicity in rats at exposures&gt;2 times the maximum recommended human exposure.</p><p>&nbsp;</p><p>Adverse &nbsp;effects &nbsp;on &nbsp;fertility &nbsp;in &nbsp;male &nbsp;and &nbsp;female &nbsp;rats &nbsp;were &nbsp;only &nbsp;observed &nbsp;at &nbsp;exposures sufficiently in excess of therapeutic exposure. Adverse effects on male reproductive organs and sperm parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were associated with spontaneous degenerative processes in male reproductive organs in the rat. Therefore the effects were considered of little or no clinical relevance.</p><p>&nbsp;</p><p>Pregabalin is not genotoxic based on results of a battery of in vitro and in vivo tests.</p><p>Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. No tumours were observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended &nbsp;clinical dose of 600 mg/day. In mice, no increased incidence of tumours was found at exposures similar to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher exposures. The nongenotoxic mechanism of pregabalin-induced&nbsp; &nbsp;tumor&nbsp; &nbsp;formation&nbsp; &nbsp;in &nbsp;mice&nbsp; &nbsp;involves&nbsp; &nbsp;platelet&nbsp; &nbsp;changes&nbsp; &nbsp;and&nbsp; &nbsp;associated endothelial &nbsp;cell proliferation. &nbsp;These platelet changes &nbsp;were not present &nbsp;in rats or in humans based on short term and limited long term clinical data. There is no evidence to suggest an associated risk to humans.</p><p>In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult</p><p>rats. However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). Effects on the estrus cycle were observed at 5-fold the human therapeutic &nbsp;exposure. &nbsp;Reduced &nbsp;acoustic &nbsp;startle &nbsp;response &nbsp;was &nbsp;observed &nbsp;in&nbsp; juvenile &nbsp;rats &nbsp;1-2 weeks after exposure at&gt;2 times the human therapeutic exposure. Nine weeks after exposure, this effect was no longer observable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose NF Fast Flow.</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Starch (1500).</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Purified Talc.</p><p>Capsule &nbsp;Shell (Body and Cap) Contains of</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gelatin</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Titanium Dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&minus; Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years/24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30oC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Clear PVC/PVDC blister strips and aluminium foil</p><p>- &nbsp;Each unit carton contains 30 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DAMMAM PHARMA 
P.O Box 8464
Dammam 31482
Saudi Arabia


Manufactured by SPIMACO 
AlQassim pharmaceutical plant 
Saudi Pharmaceutical Industries & 
Medical Appliance Corporation. 
Saudi Arabia.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>